Black Diamond Therapeutics (NASDAQ:BDTX) Announces Earnings Results, Beats Expectations By $0.09 EPS

Black Diamond Therapeutics (NASDAQ:BDTX) announced its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09, Zacks reports.

Black Diamond Therapeutics Stock Performance

Shares of Black Diamond Therapeutics stock traded down $0.11 during trading on Thursday, hitting $3.18. 405,912 shares of the stock traded hands, compared to its average volume of 767,657. The stock has a market cap of $179.70 million, a P/E ratio of -2.12 and a beta of 2.51. Black Diamond Therapeutics has a twelve month low of $1.62 and a twelve month high of $7.66. The company has a fifty day moving average price of $4.15 and a two-hundred day moving average price of $5.01.

Analyst Upgrades and Downgrades

BDTX has been the topic of a number of research analyst reports. Piper Sandler lifted their price target on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Wedbush reissued an “outperform” rating and set a $16.00 price target on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th. Raymond James began coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.